{"pub": "marketwatch", "url": "https://marketwatch.com/story/acceleron-pharma-stock-down-4-after-company-halts-treatment-trial-2019-09-16", "downloaded_at": "2019-09-16 23:11:23.550884+00:00", "title": "Acceleron Pharma stock down 4% after company halts treatment trial", "language": "en", "text": "Shares of Acceleron Pharma Inc. XLRN, +1.71% fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type of muscular dystrophy showed no evidence of benefits relative to a placebo. The company has stopped further clinical trials, saying it was \"disappointed\" with the results. The treatment, called ACE-083, is on a trial for another neuromuscular disorder and topline results are expected in the first quarter, Acceleron said. The stock ended the regular trading day 1.7% higher.", "description": "Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type...", "authors": ["Claudia Assis"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-09-16"}